SA
TEVA icon

Strategic Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Strategic Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,450
Closed -$242K – 166
2019
Q1 		$242K Sell
15,450
-2,000
-11% -$35.3K 0.09% 144
2018
Q4 		$269K Sell
17,450
-4,000
-19% -$82K 0.12% 128
2018
Q3 		$462K Sell
21,450
-2,000
-9% -$46.4K 0.17% 105
2018
Q2 		$570K Buy
+23,450
New +$478K 0.23% 90

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Strategic Advisors's TEVA Position: Q2 2019 in Review

Strategic Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 15,450 shares — an estimated $242K sold.

Strategic Advisors first reported a position in TEVA in Q2 2018 and held it in 4 quarters. The position peaked at $570K in Q2 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Strategic Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Strategic Advisors sold 15,450 Teva Pharmaceuticals shares in Q2 2019, an estimated $242K.
  • Strategic Advisors first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Strategic Advisors's Teva Pharmaceuticals position peaked at $570K in Q2 2018.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Strategic Advisors's 13F filing for Q2 2019, filed 22 Jul 2019.